FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Brophy Gerard
2. Issuer Name and Ticker or Trading Symbol

Avantor, Inc. [ AVTR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Biopharma Production
(Last)          (First)          (Middle)

RADNOR CORPORATE CENTER, BUILDING ONE,, SUITE 200, 100 MATSONFORD ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

1/2/2022
(Street)

RADNOR, PA 19087
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/2/2022  F(1)  6516 D$42.14 142863 D  
Common Stock 1/3/2022  M  59418 A$18.45 202281 D  
Common Stock 1/3/2022  S(2)  59418 D$40.77 (3)142863 D  
Common Stock 1/5/2022  S(2)  11551 D$38.65 (4)131312 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy) $18.45 1/3/2022  M     59418   (5)1/2/2030 Common Stock 59418.0 $0 59417 D  

Explanation of Responses:
(1) Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
(2) The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.27 to $41.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.44 to $38.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
(5) Reflects an initial grant of 178,253 stock options that vest in three equal installments beginning on January 2, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Brophy Gerard
RADNOR CORPORATE CENTER, BUILDING ONE,
SUITE 200, 100 MATSONFORD ROAD
RADNOR, PA 19087


EVP, Biopharma Production

Signatures
/s/ Scott Baker, as Attorney-in-Fact1/5/2022
**Signature of Reporting PersonDate

Avantor (NYSE:AVTR)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Avantor Charts.
Avantor (NYSE:AVTR)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Avantor Charts.